SCHEMBL4208161

SCHEMBL4208161

CCCCCOc1cc(Nc2nc(-c3ccc(F)cc3)cs2)ccc1C(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 7/20 0.48
CFTR P13569 1/20 0.48
NPC1 O15118 6/20 0.47
RAB9A P51151 6/20 0.47
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
NPY5R Q15761 1/20 0.47
POLB P06746 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP1B1 Q16678 1/20 0.47
MEN1 O00255 5/20 0.44
KMT2A Q03164 5/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
MAPK1 P28482 1/20 0.44
VCP P55072 1/20 0.43
PTGS2 P35354 1/20 0.42
MCHR1 Q99705 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4218351 0.99 ALOX5 (0.47) ALOX5CFTRNPC1RAB9AMAPT
SCHEMBL206916 0.92 ALOX5 (0.48) ALOX5CFTRNPC1RAB9AMAPT
SCHEMBL206430 0.91 ALOX5 (0.47) ALOX5CFTRNPC1RAB9AMAPT
SCHEMBL4208148 0.86 ALOX5 (0.50) ALOX5CFTRNPC1RAB9AMAPT
SCHEMBL3130357 0.86 ALOX5 (0.45) ALOX5NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3130311 0.85 ALOX5 (0.44) ALOX5NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3128249 0.85 MEN1 (0.57) NPC1RAB9AMAPTSMN1; SMN2TDP1
SCHEMBL3124981 0.84 MEN1 (0.56) NPC1RAB9AMAPTSMN1; SMN2TDP1
SCHEMBL2700258 0.84 ALOX5 (0.59) ALOX5MAPTTDP1MEN1KMT2A
SCHEMBL206595 0.84 MAPT (0.46) ALOX5NPC1RAB9AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183263-B2 Heteroaryl substituted thiazoles ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-22 US disclosed
US-8183263-B2 Heteroaryl substituted thiazoles ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-22 US disclosed
US-8183263-B2 Heteroaryl substituted thiazoles ACHILLION PHARMACEUTICALS, INC. (US) 2012-05-22 US disclosed
US-20090041720-A1 HETEROARYL SUBSTITUTED THIAZOLES ACHILLION PHARMACEUTICALS, INC. (US) 2009-02-12 US disclosed
US-20090041720-A1 HETEROARYL SUBSTITUTED THIAZOLES ACHILLION PHARMACEUTICALS, INC. (US) 2009-02-12 US disclosed
US-20090041720-A1 HETEROARYL SUBSTITUTED THIAZOLES ACHILLION PHARMACEUTICALS, INC. (US) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090041720-A1 HETEROARYL SUBSTITUTED THIAZOLES CYP3A43, CYP3A7, HAVCR2 ALOX5 3440/4885CFTR 83/4885NPC1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.